Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J2CW | ISIN: US4626292050 | Ticker-Symbol: I7G0
Siehe auch IPSEN SA
Frankfurt
27.06.25 | 08:02
25,600 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IPSEN SA ADR Chart 1 Jahr
5-Tage-Chart
IPSEN SA ADR 5-Tage-Chart

Aktuelle News zur IPSEN SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IPSEN SA ADR Aktie jetzt für 0€ handeln
DoIpsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours2
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 20251
20.06.Madrigal, Ipsen, SpringWorks get EU backing for their drugs2
20.06.CHMP Issues Positive Opinion On Ipsen's Cabometyx For Advanced PNET And EpNET Patients1
20.06.Exelixis, Inc.: Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors319- A regulatory decision by the European Medicines Agency is anticipated in 2025 - - In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting - Exelixis, Inc....
► Artikel lesen
20.06.Ipsen Pharma: Ipsen receives positive CHMP opinion for Cabometyx in previously treated advanced neuroendocrine tumors420If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin...
► Artikel lesen
17.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 20251
13.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 20251
12.06.Ipsen Pharma: Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
04.06.Deutsche Bank resumes Ipsen stock with buy rating citing Somatuline5
02.06.Ipsen Pharma: Ipsen S.A. - Initiation of the share buy-back program1
31.05.Ipsen Pharma: Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma589Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics...
► Artikel lesen
21.05.Ipsen Pharma: Ipsen S.A. - Annual General Meeting held on 21 May 2025403Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY)...
► Artikel lesen
20.05.GENFIT S.A.: GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo in Italy242Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
12.05.Ipsen Pharma: Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital4
07.05.Ipsen Pharma: Late-breaking exploratory data highlights the impact of IQIRVO (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis564Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO...
► Artikel lesen
06.05.Ipsen Appoints EVP, Strategy & Transformation5
06.05.Ipsen Pharma: Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation486PARIS, FRANCE, 06 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation...
► Artikel lesen
30.04.Ipsen Pharma: Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting1
28.04.GENFIT S.A.: Positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025272Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1